Astellas and Medivation may have disappointed analysts with their first-quarter Xtandi sales. But recent script numbers suggest the disappointment may be short-lived--and that the prostate cancer pill may be gaining ground on its head-to-head rival, Johnson & Johnson's Zytiga.
Japanese pharma giant Astellas is entering the booming field of immuno-oncology, pairing up with Cambridge, MA's Potenza Therapeutics to work on a wide variety of treatments that use the body's natural defenses to combat cancer.
Japan's Astellas Pharma and U.K.-based biotech Potenza Therapeutics announced a R&D effort into immuno-oncology therapies centered on checkpoint pathways, co-stimulatory signals and regulatory T cells that could lead to a buyout.
Roche's Ventana Medical Systems announced a companion diagnostic agreement centered around Astellas Pharma's cancer fighting ASP5878.
Astellas Pharma has optioned the rights to be the first to negotiate global exclusive research-and-develop rights for a leukemia drug the University of Texas is set to test in early-stage trials in the United States. In return, Astellas is to provide $26 million in funding through two Phase I stages.
Japan's Astellas Pharma has filed with Japan's Pharmaceutical and Medical Devices Agency for approval of PCSK9 inhibitor evolocumab for high cholesterol under the Amgen Astellas BioPharma joint venture.
The FDA offers incentives for developing products that target life-threatening infections, and Astellas just became the latest drugmaker to take advantage.
Japanese pharma giant Astellas won FDA approval for an antifungal treatment targeting two rare but dangerous infections, the latest drugmaker to take advantage of new incentives for anti-infective products.
Astellas Pharma is getting a piece of the vaccine pie. The Japanese company is joining forces with U.S.-based Immunomic Therapeutics to develop the latter's vaccine to treat allergies caused by Japanese red cedar.
Japanese pharma giant Astellas is the latest drugmaker to make its clinical trial data available to outside researchers, increasing its R&D transparency but stopping short of some industry trailblazers.